Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Clinical and Translational Research Challenges in Biliary Tract Cancers

Author(s): Angela Lamarca, Melissa Frizziero, Mairéad G. McNamara and Juan W. Valle*

Volume 27, Issue 29, 2020

Page: [4756 - 4777] Pages: 22

DOI: 10.2174/0929867327666200123090153

Price: $65

Abstract

Background: Biliary Tract Cancers (BTC) are rare malignancies with a poor prognosis. There are many challenges encountered in treating these patients in daily practice as well as in clinical, translational and basic research.

Objective: This review summarises the most relevant challenges in clinical and translational research in BTCs and suggests potential solutions towards an improvement in quality of life and outcomes of patients diagnosed with such malignancies.

Findings: The main challenge is the low number of patients with BTCs, complicated by the aggressive natural behaviour of cancer and the lack of funding sources for research. In addition, the clinical characteristics of these patients and the specific cancer-related complications challenge clinical research and clinical trial recruitment. It is worth highlighting that BTCs are a group of different malignancies (cholangiocarcinoma, gallbladder cancer and ampullary cancer) rather than a unique homogeneous disease. These subgroups differ not only in molecular aspects, but also in clinical and demographic characteristics. In addition, tailored imaging and quality of life assessment are required to tackle some of the issues specific to BTCs. Finally, difficulties in tissue acquisition both in terms of biopsy size and inclusion of sufficient tumour within the samples, may adversely impact translational and basic research.

Conclusion: Increasing awareness among patients and clinicians regarding BTC and the need for further research and treatment development may address some of the main challenges in BTC research. International collaboration is mandatory to progress the field.

Keywords: Biliary tract cancer, Cholangiocarcinoma, Gallbladder, Ampulla, Research, Challenges, Clinical, Translational.

« Previous Next »
[1]
Takada, T.; Amano, H.; Yasuda, H.; Nimura, Y.; Matsushiro, T.; Kato, H.; Nagakawa, T.; Nakayama, T. Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer, 2002, 95(8), 1685-1695.
[http://dx.doi.org/10.1002/cncr.10831] [PMID: 12365016]
[2]
Valle, J.W.; Borbath, I.; Khan, S.A.; Huguet, F.; Gruenberger, T.; Arnold, D. ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2016, 27(Suppl. 5), v28-v37.
[http://dx.doi.org/10.1093/annonc/mdw324] [PMID: 27664259]
[3]
Amin, M.B.; Edge, S.; Greene, F.; Byrd, D.R.; Brookland, R.K.; Washington, M.K.; Gershenwald, J.E.; Compton, C.C.; Hess, K.R.; Sullivan, D.C.; Jessup, J.M.; Brierley, J.D.; Gaspar, L.E.; Schilsky, R.L.; Balch, C.M.; Winchester, D.P.; Asare, E.A.; Madera, M.; Gress, D.M.; Meyer, L.R. (Eds.). AJCC Cancer Staging Manual; Springer-Verlag: New York., 2010. Ref Type: Edited Book.
[4]
Tyson, G.L.; El-Serag, H.B. Risk factors for cholangiocarcinoma. Hepatology, 2011, 54(1), 173-184.
[http://dx.doi.org/10.1002/hep.24351] [PMID: 21488076]
[5]
Zatonski, W.A.; Lowenfels, A.B.; Boyle, P.; Maisonneuve, P.; Bueno de Mesquita, H.B.; Ghadirian, P.; Jain, M.; Przewozniak, K.; Baghurst, P.; Moerman, C.J.; Simard, A.; Howe, G.R.; McMichael, A.J.; Hsieh, C.C.; Walker, A.M. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J. Natl. Cancer Inst., 1997, 89(15), 1132-1138.
[http://dx.doi.org/10.1093/jnci/89.15.1132] [PMID: 9262251]
[6]
Chapman, R.W. Risk factors for biliary tract carcinogenesis. Ann. Oncol., 1999, 10(Suppl. 4), 308-311.
[http://dx.doi.org/10.1093/annonc/10.suppl_4.S308 ] [PMID: 10436847]
[7]
Banales, J.M.; Cardinale, V.; Carpino, G.; Marzioni, M.; Andersen, J.B.; Invernizzi, P.; Lind, G.E.; Folseraas, T.; Forbes, S.J.; Fouassier, L.; Geier, A.; Calvisi, D.F.; Mertens, J.C.; Trauner, M.; Benedetti, A.; Maroni, L.; Vaquero, J.; Macias, R.I.; Raggi, C.; Perugorria, M.J.; Gaudio, E.; Boberg, K.M.; Marin, J.J.; Alvaro, D. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol., 2016, 13(5), 261-280.
[http://dx.doi.org/10.1038/nrgastro.2016.51] [PMID: 27095655]
[8]
Wang, Y.; Li, J.; Xia, Y.; Gong, R.; Wang, K.; Yan, Z.; Wan, X.; Liu, G.; Wu, D.; Shi, L.; Lau, W.; Wu, M.; Shen, F. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J. Clin. Oncol., 2013, 20(31), 1188-1195.
[http://dx.doi.org/10.1200/JCO.2012.41.5984] [PMID: 23358969]
[9]
Wang, S.J.; Lemieux, A.; Kalpathy-Cramer, J.; Ord, C.B.; Walker, G.V.; Fuller, C.D.; Kim, J.S.; Thomas, C.R., Jr Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J. Clin. Oncol., 2011, 29(35), 4627-4632.
[http://dx.doi.org/10.1200/JCO.2010.33.8020] [PMID: 22067404]
[10]
Bridgewater, J.; Lopes, A.; Wasan, H.; Malka, D.; Jensen, L.; Okusaka, T.; Knox, J.; Wagner, D.; Cunningham, D.; Shannon, J.; Goldstein, D.; Moehler, M.; Bekaii-Saab, T.; McNamara, M.G.; Valle, J.W. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann. Oncol., 2016, 27(1), 134-140.
[http://dx.doi.org/10.1093/annonc/mdv483] [PMID: 26483051]
[11]
Weber, S.M.; DeMatteo, R.P.; Fong, Y.; Blumgart, L.H.; Jarnagin, W.R. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann. Surg., 2002, 235(3), 392-399.
[http://dx.doi.org/10.1097/00000658-200203000-00011] [PMID: 11882761]
[12]
Madariaga, J.R.; Iwatsuki, S.; Todo, S.; Lee, R.G.; Irish, W.; Starzl, T.E. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann. Surg., 1998, 227(1), 70-79.
[http://dx.doi.org/10.1097/00000658-199801000-00011] [PMID: 9445113]
[13]
Hanazaki, K.; Kajikawa, S.; Shimozawa, N.; Shimada, K.; Hiraguri, M.; Koide, N.; Adachi, W.; Amano, J. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology, 2002, 49(44), 311-316.
[PMID: 11995440]
[14]
Tanaka, S.; Hirohashi, K.; Tanaka, H.; Yamamoto, T.; Kubo, S.; Shuto, T.; Takemura, S.; Kinoshita, H. Prognostic factors in patients with carcinoma of the papilla of Vater. Hepatogastroenterology, 2002, 49(46), 1116-1119.
[PMID: 12143216]
[15]
Miwa, S.; Miyagawa, S.; Kobayashi, A.; Akahane, Y.; Nakata, T.; Mihara, M.; Kusama, K.; Soeda, J.; Ogawa, S. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J. Gastroenterol., 2006, 41(9), 893-900.
[http://dx.doi.org/10.1007/s00535-006-1877-z] [PMID: 17048054]
[16]
Jan, Y.Y.; Yeh, C.N.; Yeh, T.S.; Hwang, T.L.; Chen, M.F. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J. Surg., 2005, 29(7), 894-898.
[http://dx.doi.org/10.1007/s00268-005-7763-7] [PMID: 15951931]
[17]
Riall, T.S.; Cameron, J.L.; Lillemoe, K.D.; Campbell, K.A.; Sauter, P.K.; Coleman, J.; Abrams, R.A.; Laheru, D.; Hruban, R.H.; Yeo, C.J. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J. Gastrointest. Surg., 2005, 9(9), 1191-1204.
[http://dx.doi.org/10.1016/j.gassur.2005.08.034] [PMID: 16332474]
[18]
Wade, T.P.; Prasad, C.N.; Virgo, K.S.; Johnson, F.E. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987-1991. J. Surg. Oncol., 1997, 64(3), 242-245.
[http://dx.doi.org/10.1002/(SICI)1096-9098(199703)64:3< 242:AID-JSO12>3.0.CO;2-6] [PMID: 9121157]
[19]
Lamarca, A. Should patients with resected bile duct cancer receive an adjuvant treatment? J. Oncopathol., 2014, 2(4), 57-68. (12).
[http://dx.doi.org/10.13032/tjop.2052-5931.100109]
[20]
Horgan, A.M.; Amir, E.; Walter, T.; Knox, J.J. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J. Clin. Oncol., 2012, 30(16), 1934-1940.
[http://dx.doi.org/10.1200/JCO.2011.40.5381] [PMID: 22529261]
[21]
Neoptolemos, J.P.; Moore, M.J.; Cox, T.F.; Valle, J.W.; Palmer, D.H.; McDonald, A.C.; Carter, R.; Tebbutt, N.C.; Dervenis, C.; Smith, D.; Glimelius, B.; Charnley, R.M.; Lacaine, F.; Scarfe, A.G.; Middleton, M.R.; Anthoney, A.; Ghaneh, P.; Halloran, C.M.; Lerch, M.M.; Oláh, A.; Rawcliffe, C.L.; Verbeke, C.S.; Campbell, F.; Büchler, M.W. European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 2012, 308(2), 147-156.
[http://dx.doi.org/10.1001/jama.2012.7352] [PMID: 22782416]
[22]
Bariani, G.M.; Braghiroli, M.I.; Riechelmann, R.P. Poor evidence to standardize adjuvant treatment for patients with biliary tract cancer. J. Clin. Oncol., 2012, 30(33), 4173.
[http://dx.doi.org/10.1200/JCO.2012.44.1634] [PMID: 23071221]
[23]
Julien Edeline, Franck Bonnetain, Jean Marc Phelip, Jérôme Watelet, Pascal Hammel, Jean-Paul Joly, Meher Ben Abdelghani, Olivier Rosmorduc, Karine Bouhier-Leporrier, Jean- Louis Jouve, Roger Faroux, Véronique Guerin Meyer, Eric Assenat, Jean Francois Seitz, David Malka, Christophe Louvet, Aurelie Bertaut, Beata Juzyna, Trevor Stanbury, Eveline Boucher. emox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12- ACCORD 18 (UNICANCER GI) phase III trial. J. Clin. Oncol., 2017, 35(suppl 4S; abstract 225)
[24]
Ben-Josef, E.; Guthrie, K.A.; El-Khoueiry, A.B. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J. Clin. Oncol., 2015, 20(33), 2617-2622.
[25]
John Neil Primrose, Richard Fox, Daniel H. Palmer, Raj Prasad, Darius Mirza, David Alan Anthoney, Philippa Corrie, Stephen Falk, Harpreet Singh Wasan, Paul J. Ross, Lucy R. Wall, Jonathan Wadsley, T.R. Jeffry Evans, Deborah Stocken, Raaj Praseedom, David Cunningham, O James Garden, Clive Stubbs, Juan W. Valle, John A. Bridgewater. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J. Clin. Oncol., 2017, 35(15 Suppl)
[26]
ClinicalTrials.gov. ClinicalTrials.gov, www.clinicaltrials.gov [December 2019];2020
[27]
Ruys, A.T.; van Haelst, S.; Busch, O.R.; Rauws, E.A.; Gouma, D.J.; van Gulik, T.M. Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World J. Surg., 2012, 36(9), 2179-2186.
[http://dx.doi.org/10.1007/s00268-012-1638-5] [PMID: 22569746]
[28]
Raderer, M.; Hejna, M.H.; Valencak, J.B.; Kornek, G.V.; Weinländer, G.S.; Bareck, E.; Lenauer, J.; Brodowicz, T.; Lang, F.; Scheithauer, W. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology, 1999, 56(3), 177-180.
[http://dx.doi.org/10.1159/000011961] [PMID: 10202270]
[29]
Okusaka, T.; Nakachi, K.; Fukutomi, A.; Mizuno, N.; Ohkawa, S.; Funakoshi, A.; Nagino, M.; Kondo, S.; Nagaoka, S.; Funai, J.; Koshiji, M.; Nambu, Y.; Furuse, J.; Miyazaki, M.; Nimura, Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br. J. Cancer, 2010, 103(4), 469-474.
[http://dx.doi.org/10.1038/sj.bjc.6605779] [PMID: 20628385]
[30]
Tao, R.; Krishnan, S. Bhosale, PR Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J. Clin. Oncol., 2016, 20(34), 219-226.
[31]
Al-Adra, D.P.; Gill, R.S.; Axford, S.J.; Shi, X.; Kneteman, N.; Liau, S.S. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur. J. Surg. Oncol., 2015, 41(1), 120-127.
[http://dx.doi.org/10.1016/j.ejso.2014.09.007] [PMID: 25449754]
[32]
Edeline, J.; Du, F.L.; Rayar, M.; Rolland, Y.; Beuzit, L.; Boudjema, K.; Rohou, T.; Latournerie, M.; Campillo-Gimenez, B.; Garin, E.; Boucher, E. Glass Microspheres 90Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma. Clin. Nucl. Med., 2015, 40(11), 851-855.
[http://dx.doi.org/10.1097/RLU.0000000000000904] [PMID: 26204219]
[33]
Eckel, F.; Schmid, R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br. J. Cancer, 2007, 96(6), 896-902.
[http://dx.doi.org/10.1038/sj.bjc.6603648] [PMID: 17325704]
[34]
Tsavaris, N.; Kosmas, C.; Gouveris, P.; Gennatas, K.; Polyzos, A.; Mouratidou, D.; Tsipras, H.; Margaris, H.; Papastratis, G.; Tzima, E.; Papadoniou, N.; Karatzas, G.; Papalambros, E. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest. New Drugs, 2004, 22(2), 193-198.
[http://dx.doi.org/10.1023/B:DRUG.0000011797.09549.53] [PMID: 14739669]
[35]
Glimelius, B.; Hoffman, K.; Sjödén, P.O.; Jacobsson, G.; Sellström, H.; Enander, L.K.; Linné, T.; Svensson, C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol., 1996, 7(6), 593-600.
[http://dx.doi.org/10.1093/oxfordjournals.annonc.a010676] [PMID: 8879373]
[36]
Valle, J.; Wasan, H.; Palmer, D.H.; Cunningham, D.; Anthoney, A.; Maraveyas, A.; Madhusudan, S.; Iveson, T.; Hughes, S.; Pereira, S.P.; Roughton, M.; Bridgewater, J. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med., 2010, 362(14), 1273-1281.
[http://dx.doi.org/10.1056/NEJMoa0908721] [PMID: 20375404]
[37]
Lamarca, A.; Benafif, S.; Ross, P.; Bridgewater, J.; Valle, J.W. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. Eur. J. Cancer, 2015, 51(13), 1694-1703.
[http://dx.doi.org/10.1016/j.ejca.2015.05.018] [PMID: 26066735]
[38]
Bridgewater, J.; Palmer, D.; Cunningham, D.; Iveson, T.; Gillmore, R.; Waters, J.; Harrison, M.; Wasan, H.; Corrie, P.; Valle, J. Outcome of second-line chemotherapy for biliary tract cancer. Eur. J. Cancer, 2013, 49(6), 1511.
[http://dx.doi.org/10.1016/j.ejca.2012.11.024] [PMID: 23265701]
[39]
Lamarca, A.; Hubner, R.A.; David Ryder, W.; Valle, J.W. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann. Oncol., 2014, 25(12), 2328-2338.
[http://dx.doi.org/10.1093/annonc/mdu162] [PMID: 24769639]
[40]
Walter, T.; Horgan, A.M.; McNamara, M.; McKeever, L.; Min, T.; Hedley, D.; Serra, S.; Krzyzanowska, M.K.; Chen, E.; Mackay, H.; Feld, R.; Moore, M.; Knox, J.J. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur. J. Cancer, 2013, 49(2), 329-335.
[http://dx.doi.org/10.1016/j.ejca.2012.08.003] [PMID: 22947649]
[41]
Oh, S.Y.; Jeong, C.Y.; Hong, S.C.; Kim, T.H.; Ha, C.Y.; Kim, H.J.; Lee, G.W.; Hwang, I.G.; Jang, J.S.; Kwon, H.C.; Kang, J.H. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest. New Drugs, 2011, 29(5), 1066-1072.
[http://dx.doi.org/10.1007/s10637-010-9417-3] [PMID: 20358256]
[42]
Lee, S.; Oh, S.Y.; Kim, B.G.; Kwon, H.C.; Kim, S.H.; Rho, M.H.; Kim, Y.H.; Rho, M.S.; Jeong, J.S.; Kim, H.J. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am. J. Clin. Oncol., 2009, 32(4), 348-352.
[http://dx.doi.org/10.1097/COC.0b013e31818c08ff] [PMID: 19363436]
[43]
Sasaki, T.; Isayama, H.; Nakai, Y.; Mizuno, S.; Yamamoto, K.; Yagioka, H.; Yashima, Y.; Kawakubo, K.; Kogure, H.; Togawa, O.; Matsubara, S.; Ito, Y.; Sasahira, N.; Hirano, K.; Tsujino, T.; Toda, N.; Tada, M.; Omata, M.; Koike, K. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest. New Drugs, 2012, 30(2), 708-713.
[http://dx.doi.org/10.1007/s10637-010-9553-9] [PMID: 20924641]
[44]
Angela Lamarca DPHSWPRYTMAAea. ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5- FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J. Clin Oncol, 2019, 37(suppl; abstr 4003)
[45]
Lubner, S.J.; Mahoney, M.R.; Kolesar, J.L. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J. Clin. Oncol., 2010, 20(28), 3491-3497.
[46]
Valle, J.W.; Wasan, H.; Lopes, A.; Backen, A.C.; Palmer, D.H.; Morris, K.; Duggan, M.; Cunningham, D.; Anthoney, D.A.; Corrie, P.; Madhusudan, S.; Maraveyas, A.; Ross, P.J.; Waters, J.S.; Steward, W.P.; Rees, C.; Beare, S.; Dive, C.; Bridgewater, J.A. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol., 2015, 16(8), 967-978.
[http://dx.doi.org/10.1016/S1470-2045(15)00139-4] [PMID: 26179201]
[47]
Lee, J.K.; Capanu, M.; O’Reilly, E.M. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br. J. Cancer, 2013, 20(109), 915-919.
[http://dx.doi.org/10.1038/bjc.2013.432]
[48]
Malka, D.; Cervera, P.; Foulon, S.; Trarbach, T.; de la Fouchardière, C.; Boucher, E.; Fartoux, L.; Faivre, S.; Blanc, J.F.; Viret, F.; Assenat, E.; Seufferlein, T.; Herrmann, T.; Grenier, J.; Hammel, P.; Dollinger, M.; André, T.; Hahn, P.; Heinemann, V.; Rousseau, V.; Ducreux, M.; Pignon, J.P.; Wendum, D.; Rosmorduc, O.; Greten, T.F. BINGO investigators. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol., 2014, 15(8), 819-828.
[http://dx.doi.org/10.1016/S1470-2045(14)70212-8] [PMID: 24852116]
[49]
Valle, J.W.; Lamarca, A.; Goyal, L.; Barriuso, J.; Zhu, A.X. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov., 2017, 7(9), 943-962.
[http://dx.doi.org/10.1158/2159-8290.CD-17-0245] [PMID: 28818953]
[50]
G.K.Abou-Alfa TMMMJRKKSLea. ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Annals of Oncology, 2019, 30(suppl_5), v851-v934.
[http://dx.doi.org/10.1093/annonc/mdz394]
[51]
Javle, M.; Lowery, M.; Shroff, R.T.; Phase, I.I. Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J. Clin. Oncol., 2018, 20(36), 276-282.
[52]
PubMed. PubMed, [December 2019];2020 [www.ncbi.nlm.nih.gov/pubmed]
[53]
Patel, T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology, 2001, 33(6), 1353-1357.
[http://dx.doi.org/10.1053/jhep.2001.25087] [PMID: 11391522]
[54]
Bertuccio, P.; Bosetti, C.; Levi, F.; Decarli, A.; Negri, E.; La Vecchia, C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann. Oncol., 2013, 24(6), 1667-1674.
[http://dx.doi.org/10.1093/annonc/mds652] [PMID: 23378539]
[55]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin., 2016, 66(1), 7-30.
[http://dx.doi.org/10.3322/caac.21332] [PMID: 26742998]
[56]
McGlynn, K.A.; Tarone, R.E.; El-Serag, H.B. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol. Biomarkers Prev., 2006, 15(6), 1198-1203.
[http://dx.doi.org/10.1158/1055-9965.EPI-05-0811] [PMID: 16775181]
[57]
Greenlee, R.T.; Murray, T.; Bolden, S.; Wingo, P.A. Cancer statistics, 2000. CA Cancer J. Clin., 2000, 50(1), 7-33.
[http://dx.doi.org/10.3322/canjclin.50.1.7] [PMID: 10735013]
[58]
Jemal, A.; Murray, T.; Samuels, A.; Ghafoor, A.; Ward, E.; Thun, M. J. Cancer statistics, 2003. CA Cancer J. Clin., 2003, 53(1), 5-26.
[http://dx.doi.org/10.3322/canjclin.53.1.5] [PMID: 12568441]
[59]
Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R.C.; Ghafoor, A.; Feuer, E.J.; Thun, M. J. Cancer statistics, 2005. CA Cancer J. Clin., 2005, 55(1), 10-30.
[http://dx.doi.org/10.3322/canjclin.55.1.10] [PMID: 15661684]
[60]
Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J. Cancer statistics, 2006. CA Cancer J. Clin., 2006, 56(2), 106-130.
[http://dx.doi.org/10.3322/canjclin.56.2.106] [PMID: 16514137]
[61]
Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007. CA Cancer J. Clin., 2007, 57(1), 43-66.
[http://dx.doi.org/10.3322/canjclin.57.1.43] [PMID: 17237035]
[62]
Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59(4), 225-249.
[http://dx.doi.org/10.3322/caac.20006] [PMID: 19474385]
[63]
Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin., 2010, 60(5), 277-300.
[http://dx.doi.org/10.3322/caac.20073] [PMID: 20610543]
[64]
Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin., 2013, 63(1), 11-30.
[http://dx.doi.org/10.3322/caac.21166] [PMID: 23335087]
[65]
Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin., 2014, 64(1), 9-29.
[http://dx.doi.org/10.3322/caac.21208] [PMID: 24399786]
[66]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin., 2015, 65(1), 5-29.
[http://dx.doi.org/10.3322/caac.21254] [PMID: 25559415]
[67]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin., 2017, 67(1), 7-30.
[http://dx.doi.org/10.3322/caac.21387] [PMID: 28055103]
[68]
Bosetti, C.; Bertuccio, P.; Malvezzi, M.; Levi, F.; Chatenoud, L.; Negri, E.; La Vecchia, C. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann. Oncol., 2013, 24(10), 2657-2671.
[http://dx.doi.org/10.1093/annonc/mdt301] [PMID: 23921790]
[69]
Gatta, G.; van der Zwan, J.M.; Casali, P.G.; Siesling, S.; Dei Tos, A.P.; Kunkler, I.; Otter, R.; Licitra, L.; Mallone, S.; Tavilla, A.; Trama, A.; Capocaccia, R. RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur. J. Cancer, 2011, 47(17), 2493-2511.
[http://dx.doi.org/10.1016/j.ejca.2011.08.008] [PMID: 22033323]
[70]
Cancer52. Cancer52, [December 2019).]; http://www.cancer52.org/uk2020/
[71]
Keat, N.; Law, K.; Seymour, M.; Welch, J.; Trimble, T.; Lascombe, D.; Negrouk, A. International rare cancers initiative. Lancet Oncol., 2013, 14(2), 109-110.
[http://dx.doi.org/10.1016/S1470-2045(12)70570-3] [PMID: 23369681]
[72]
AMMF. Alan Morement Memorial Fund, 2020. http://ammf.org.uk/
[73]
CCF. The Cholangiocarcinoma Foundation, [December 2019];http://cholangiocarcinoma org/2020
[74]
The Bili Project Foundation. The Bili Project Foundation, [December 2019]; http://thebiliproject org/2020
[75]
IHPBA. IHPBA, [December 2019]; http://www.ihpba.org/2020
[76]
ICRN. ICRN, [December 2019]; http://cholangiocarcinoma.org/international-cholangiocarcinoma-researchnetwork/2020
[77]
ENS-CCA. ENS-CCA, [December 2019]; http://www.enscca.org/2020
[78]
Cancer Research UK. Making a impact in rarer cancers – the ABC02 trial., http://scienceblog cancerresearchuk.org/2010/04/08/making-a-impact-in-rarer-cancers-%e2%80%93-the-abc02-trial/ [19th March 2017];2017
[79]
NIH (National Institute of Health). Biliary tract cancer; category: rare cancer., https://rarediseases.info.nih.gov/diseases/5924/biliary-tract-cancer [19th March 2017]; 2017
[80]
Shin, H.R.; Oh, J.K.; Masuyer, E.; Curado, M.P.; Bouvard, V.; Fang, Y.Y.; Wiangnon, S.; Sripa, B.; Hong, S.T. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci., 2010, 101(3), 579-585.
[http://dx.doi.org/10.1111/j.1349-7006.2009.01458.x] [PMID: 20085587]
[81]
Baer, A.R.; Michaels, M.; Good, M.J.; Schapira, L. Engaging referring physicians in the clinical trial process. J. Oncol. Pract., 2012, 8(1), e8-e10.
[http://dx.doi.org/10.1200/JOP.2011.000476] [PMID: 22548019]
[82]
Agarwal, R.; Sendilnathan, A.; Siddiqi, N.I.; Gulati, S.; Ghose, A.; Xie, C.; Olowokure, O.O. Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J. Gastrointest. Oncol., 2016, 7(6), 996-1003.
[http://dx.doi.org/10.21037/jgo.2016.09.10] [PMID: 28078124]
[83]
Horgan, A.; Knox, J.; Aneja, P.; Le, L.; McKeever, E.; McNamara, M. Patterns of care and treatment outcomes in older patients with biliary tract cancer. Oncotarget, 2015, 6(42), 44995-45004.
[http://dx.doi.org/10.18632/oncotarget.5707] [PMID: 26575326]
[84]
Grunnet, M.; Christensen, I.J.; Lassen, U.; Jensen, L.H.; Lydolph, M.; Knox, J.J.; McNamara, M.G.; Jitlal, M.; Wasan, H.; Bridgewater, J.; Valle, J.W.; Mau-Sorensen, M. Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. Eur. J. Cancer, 2015, 51(11), 1381-1388.
[http://dx.doi.org/10.1016/j.ejca.2015.04.011] [PMID: 25971532]
[85]
Lamarca, A.; Rigby, C.; McNamara, M.G.; Hubner, R.A.; Valle, J.W. Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. World J. Gastroenterol., 2016, 22(26), 6065-6075.
[http://dx.doi.org/10.3748/wjg.v22.i26.6065] [PMID: 27468198]
[86]
The Cholangiocarcinoma Foundation (CCF). Just Diagnosed with Cholangiocarcinoma? Here are some next steps, http://cholangiocarcinoma org/newly-dx/2017 [20th March 2017];
[87]
Donovan, J.L.; Paramasivan, S.; de Salis, I.; Toerien, M. Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials. Trials, 2014, 15, 5.
[http://dx.doi.org/10.1186/1745-6215-15-5] [PMID: 24393291]
[88]
Thoma, A.; Farrokhyar, F.; McKnight, L.; Bhandari, M. Practical tips for surgical research: how to optimize patient recruitment. Can. J. Surg., 2010, 53(3), 205-210.
[PMID: 20507795]
[89]
Krischer, J.; Cronholm, P.F.; Burroughs, C.; McAlear, C.A.; Borchin, R.; Easley, E.; Davis, T.; Kullman, J.; Carette, S.; Khalidi, N.; Koening, C.; Langford, C.A.; Monach, P.; Moreland, L.; Pagnoux, C.; Specks, U.; Sreih, A.G.; Ytterberg, S.; Merkel, P.A. Vasculitis Clinical Research Consortium. Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. J. Med. Internet Res., 2017, 19(2), e50.
[http://dx.doi.org/10.2196/jmir.6798] [PMID: 28246067]
[90]
Caplan, A.; Friesen, P. Health disparities and clinical trial recruitment: Is there a duty to tweet? PLoS Biol., 2017, 15(3), e2002040.
[http://dx.doi.org/10.1371/journal.pbio.2002040] [PMID: 28249024]
[91]
Henson, D.E.; Albores-Saavedra, J.; Corle, D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer, 1992, 70(6), 1493-1497.
[http://dx.doi.org/10.1002/1097-0142(19920915)70:6<1493: AID-CNCR2820700608>3.0.CO;2-U] [PMID: 1516000]
[92]
Gourgiotis, S.; Kocher, H.M.; Solaini, L.; Yarollahi, A.; Tsiambas, E.; Salemis, N.S. Gallbladder cancer. Am. J. Surg., 2008, 196(2), 252-264.
[http://dx.doi.org/10.1016/j.amjsurg.2007.11.011] [PMID: 18466866]
[93]
Gatto, M.; Alvaro, D. Cholangiocarcinoma: risk factors and clinical presentation. Eur. Rev. Med. Pharmacol. Sci., 2010, 14(4), 363-367.
[PMID: 20496549]
[94]
Heinrich, S.; Clavien, P.A. Ampullary cancer. Curr. Opin. Gastroenterol., 2010, 26(3), 280-285.
[http://dx.doi.org/10.1097/MOG.0b013e3283378eb0] [PMID: 20168227]
[95]
Bridgewater, J.; Lopes, A.; Beare, S.; Duggan, M.; Lee, D.; Ricamara, M.; McEntee, D.; Sukumaran, A.; Wasan, H.; Valle, J.W. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer, 2016, 16, 153-2174.
[http://dx.doi.org/10.1186/s12885-016-2174-8] [PMID: 26912134]
[96]
Jiang, Z.Q.; Varadhachary, G.; Wang, X.; Kopetz, S.; Lee, J.E.; Wang, H.; Shroff, R.; Katz, M.; Wolff, R.A.; Fleming, J.; Overman, M.J. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann. Oncol., 2013, 24(9), 2349-2353.
[http://dx.doi.org/10.1093/annonc/mdt191] [PMID: 23704197]
[97]
Overman, M.J.; Zhang, J.; Kopetz, S.; Davies, M.; Jiang, Z.Q.; Stemke-Hale, K.; Rümmele, P.; Pilarsky, C.; Grützmann, R.; Hamilton, S.; Hwang, R.; Abbruzzese, J.L.; Varadhachary, G.; Broom, B.; Wang, H. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One, 2013, 8(6), e65144.
[http://dx.doi.org/10.1371/journal.pone.0065144] [PMID: 23776447]
[98]
Overman, M.J.; Varadhachary, G.R.; Kopetz, S.; Adinin, R.; Lin, E.; Morris, J.S.; Eng, C.; Abbruzzese, J.L.; Wolff, R.A. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J. Clin. Oncol., 2009, 27(16), 2598-2603.
[http://dx.doi.org/10.1200/JCO.2008.19.7145] [PMID: 19164203]
[99]
Jeffrey, S. Ross, KWDVTCea. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. [ASCO Annual Meeting 2015 J Clin Oncol, 2015, 33(suppl 3; abstr 231)
[100]
Deshpande, V.; Nduaguba, A.; Zimmerman, S.M.; Kehoe, S.M.; Macconaill, L.E.; Lauwers, G.Y.; Ferrone, C.; Bardeesy, N.; Zhu, A.X.; Hezel, A.F. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer, 2011, 11, 60.
[http://dx.doi.org/10.1186/1471-2407-11-60] [PMID: 21303542]
[101]
Borger, D.R.; Tanabe, K.K.; Fan, K.C.; Lopez, H.U.; Fantin, V.R.; Straley, K.S.; Schenkein, D.P.; Hezel, A.F.; Ancukiewicz, M.; Liebman, H.M.; Kwak, E.L.; Clark, J.W.; Ryan, D.P.; Deshpande, V.; Dias-Santagata, D.; Ellisen, L.W.; Zhu, A.X.; Iafrate, A.J. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist, 2012, 17(1), 72-79.
[http://dx.doi.org/10.1634/theoncologist.2011-0386] [PMID: 22180306]
[102]
Galdy, S.; Lamarca, A.; McNamara, M.G.; Hubner, R.A.; Cella, C.A.; Fazio, N.; Valle, J.W. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev., 2017, 36(1), 141-157.
[http://dx.doi.org/10.1007/s10555-016-9645-x] [PMID: 27981460]
[103]
Riener, M.O.; Bawohl, M.; Clavien, P.A.; Jochum, W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer, 2008, 47(5), 363-367.
[http://dx.doi.org/10.1002/gcc.20540] [PMID: 18181165]
[104]
Li, M.; Zhang, Z.; Li, X.; Ye, J.; Wu, X.; Tan, Z.; Liu, C.; Shen, B.; Wang, X.A.; Wu, W.; Zhou, D.; Zhang, D.; Wang, T.; Liu, B.; Qu, K.; Ding, Q.; Weng, H.; Ding, Q.; Mu, J.; Shu, Y.; Bao, R.; Cao, Y.; Chen, P.; Liu, T.; Jiang, L.; Hu, Y.; Dong, P.; Gu, J.; Lu, W.; Shi, W.; Lu, J.; Gong, W.; Tang, Z.; Zhang, Y.; Wang, X.; Chin, Y.E.; Weng, X.; Zhang, H.; Tang, W.; Zheng, Y.; He, L.; Wang, H.; Liu, Y.; Liu, Y. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat. Genet., 2014, 46(8), 872-876.
[http://dx.doi.org/10.1038/ng.3030] [PMID: 24997986]
[105]
Pai, R.K.; Mojtahed, K.; Pai, R.K. Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. Appl. Immunohistochem. Mol. Morphol., 2011, 19(2), 133-140.
[http://dx.doi.org/10.1097/PAI.0b013e3181f09179] [PMID: 21307665]
[106]
Ross, J.S.; Wang, K.; Gay, L.; Al-Rohil, R.; Rand, J.V.; Jones, D.M.; Lee, H.J.; Sheehan, C.E.; Otto, G.A.; Palmer, G.; Yelensky, R.; Lipson, D.; Morosini, D.; Hawryluk, M.; Catenacci, D.V.; Miller, V.A.; Churi, C.; Ali, S.; Stephens, P.J. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist, 2014, 19(3), 235-242.
[http://dx.doi.org/10.1634/theoncologist.2013-0352] [PMID: 24563076]
[107]
Randall, F. Holcombe, JXMJPea. Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets. [ASCO Annual Meeting J Clin Oncol, 2015, 33(suppl 3; abstr 285)
[108]
Arai, Y.; Totoki, Y.; Hosoda, F.; Shirota, T.; Hama, N.; Nakamura, H.; Ojima, H.; Furuta, K.; Shimada, K.; Okusaka, T.; Kosuge, T.; Shibata, T. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology, 2014, 59(4), 1427-1434.
[http://dx.doi.org/10.1002/hep.26890] [PMID: 24122810]
[109]
Sia, D.; Losic, B.; Moeini, A.; Cabellos, L.; Hao, K.; Revill, K.; Bonal, D.; Miltiadous, O.; Zhang, Z.; Hoshida, Y.; Cornella, H.; Castillo-Martin, M.; Pinyol, R.; Kasai, Y.; Roayaie, S.; Thung, S.N.; Fuster, J.; Schwartz, M.E.; Waxman, S.; Cordon-Cardo, C.; Schadt, E.; Mazzaferro, V.; Llovet, J.M. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat. Commun., 2015, 6, 6087.
[http://dx.doi.org/10.1038/ncomms7087] [PMID: 25608663]
[110]
Churi, C.R.; Shroff, R.; Wang, Y.; Rashid, A.; Kang, H.C.; Weatherly, J.; Zuo, M.; Zinner, R.; Hong, D.; Meric-Bernstam, F.; Janku, F.; Crane, C.H.; Mishra, L.; Vauthey, J.N.; Wolff, R.A.; Mills, G.; Javle, M. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One, 2014, 9(12), e115383.
[http://dx.doi.org/10.1371/journal.pone.0115383] [PMID: 25536104]
[111]
Graham, R.P.; Barr Fritcher, E.G.; Pestova, E.; Schulz, J.; Sitailo, L.A.; Vasmatzis, G.; Murphy, S.J.; McWilliams, R.R.; Hart, S.N.; Halling, K.C.; Roberts, L.R.; Gores, G.J.; Couch, F.J.; Zhang, L.; Borad, M.J.; Kipp, B.R. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol., 2014, 45(8), 1630-1638.
[http://dx.doi.org/10.1016/j.humpath.2014.03.014] [PMID: 24837095]
[112]
Turner, N.; Grose, R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer, 2010, 10(2), 116-129.
[http://dx.doi.org/10.1038/nrc2780] [PMID: 20094046]
[113]
Chan-On, W.; Nairismägi, M.L.; Ong, C.K.; Lim, W.K.; Dima, S.; Pairojkul, C.; Lim, K.H.; McPherson, J.R.; Cutcutache, I.; Heng, H.L.; Ooi, L.; Chung, A.; Chow, P.; Cheow, P.C.; Lee, S.Y.; Choo, S.P.; Tan, I.B.; Duda, D.; Nastase, A.; Myint, S.S.; Wong, B.H.; Gan, A.; Rajasegaran, V.; Ng, C.C.; Nagarajan, S.; Jusakul, A.; Zhang, S.; Vohra, P.; Yu, W.; Huang, D.; Sithithaworn, P.; Yongvanit, P.; Wongkham, S.; Khuntikeo, N.; Bhudhisawasdi, V.; Popescu, I.; Rozen, S.G.; Tan, P.; Teh, B.T. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet., 2013, 45(12), 1474-1478.
[http://dx.doi.org/10.1038/ng.2806] [PMID: 24185513]
[114]
Hechtman, J.F.; Liu, W.; Sadowska, J.; Zhen, L.; Borsu, L.; Arcila, M.E.; Won, H.H.; Shah, R.H.; Berger, M.F.; Vakiani, E.; Shia, J.; Klimstra, D.S. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Mod. Pathol., 2015, 28(8), 1123-1129.
[http://dx.doi.org/10.1038/modpathol.2015.57] [PMID: 25975284]
[115]
Mafficini, A.; Amato, E.; Cataldo, I. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. Ann. Surg., 2016.
[PMID: 27611608]
[116]
Kwon, M.J.; Kim, J.W.; Jeon, J.Y.; Nam, E.S.; Cho, S.J.; Park, H.R.; Min, S.K.; Seo, J.; Min, K.W.; Choe, J.Y.; Lee, H.K. Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers. Pathol. Res. Pract., 2017, 213(4), 381-388.
[http://dx.doi.org/10.1016/j.prp.2017.01.004] [PMID: 28214200]
[117]
Yeh, B.M.; Liu, P.S.F.A.; Soto, J.A.F.A.; Corvera, C.A.; Hussain, H.K. MR imaging and CT of the biliary tract. Radiographics, 2009, 29(6), 1669-1688.
[http://dx.doi.org/10.1148/rg.296095514] [PMID: 19959515]
[118]
Mittal, P.K.; Moreno, C.C.F.A. Kalb, B.F.A.U. - Primary biliary tract malignancies: MRI spectrum and mimics with histopathological correlation. -. Abdom. Imaging, 2014.
[PMID: 25416002]
[119]
Schöfl, R. Diagnostic endoscopic retrograde cholangiopancreatography. Endoscopy, 2001, 33(2), 147-157.
[http://dx.doi.org/10.1055/s-2001-11667] [PMID: 11272217]
[120]
Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; Rubinstein, L.; Shankar, L.; Dodd, L.; Kaplan, R.; Lacombe, D.; Verweij, J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer, 2009, 45(2), 228-247.
[http://dx.doi.org/10.1016/j.ejca.2008.10.026] [PMID: 19097774]
[121]
Piscaglia, F.; Iavarone, M.; Galassi, M.; Vavassori, S.; Renzulli, M.; Forzenigo, L.V.; Granito, A.; Salvatore, V.; Sangiovanni, A.; Golfieri, R.; Colombo, M.; Bolondi, L. Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. Dig. Dis., 2015, 33(6), 735-744.
[http://dx.doi.org/10.1159/000439097] [PMID: 26488875]
[122]
Galia, M.; Taibbi, A.; Marin, D.; Furlan, A.; Dioguardi Burgio, M.; Agnello, F.; Cabibbo, G.; Van Beers, B.E.; Bartolotta, T.V.; Midiri, M.; Lagalla, R.; Brancatelli, G. Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? Diagn. Interv. Radiol., 2014, 20(3), 222-228.
[http://dx.doi.org/10.5152/dir.2014.13184] [PMID: 24509186]
[123]
Bergquist, J.R.; Groeschl, R.T.; Ivanics, T.; Shubert, C.R.; Habermann, E.B.; Kendrick, M.L.; Farnell, M.B.; Nagorney, D.M.; Truty, M.J.; Smoot, R.L. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics. HPB (Oxford), 2016, 18(11), 886-892.
[http://dx.doi.org/10.1016/j.hpb.2016.07.006] [PMID: 27546172]
[124]
Moeini, A.; Sia, D.; Zhang, Z.; Camprecios, G.; Stueck, A.; Dong, H.; Montal, R.; Torrens, L.; Martinez-Quetglas, I.; Fiel, M.I.; Hao, K.; Villanueva, A.; Thung, S.N.; Schwartz, M.E.; Llovet, J.M. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J. Hepatol., 2017, 66(5), 952-961.
[http://dx.doi.org/10.1016/j.jhep.2017.01.010] [PMID: 28126467]
[125]
Raghav, K.; Mhadgut, H.; McQuade, J.L.; Lei, X.; Ross, A.; Matamoros, A.; Wang, H.; Overman, M.J.; Varadhachary, G.R. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One, 2016, 11(5), e0154985.
[http://dx.doi.org/10.1371/journal.pone.0154985] [PMID: 27171493]
[126]
Brugge, W.; Dewitt, J.; Klapman, J.B.F.A.; Ashfaq, R.; Shidham, V.; Chhieng, D.; Kwon, R.; Baloch, Z.; Zarka, M.; Staerkel, G. Papanicolaou Society of Cytopathology. Techniques for cytologic sampling of pancreatic and bile duct lesions. Diagn. Cytopathol., 2014, 42(4), 333-337.
[http://dx.doi.org/10.1002/dc.23096] [PMID: 24554498]
[127]
Inui, K.; Yoshino, J.; Miyoshi, H. Differential diagnosis and treatment of biliary strictures. Clin. Gastroenterol. Hepatol., 2009, 7(11)(Suppl.), S79-S83.
[http://dx.doi.org/10.1016/j.cgh.2009.08.027] [PMID: 19896104]
[128]
Brugge, W.R. Advances in the endoscopic management of patients with pancreatic and biliary malignancies. South. Med. J., 2006, 99(12), 1358-1366.
[http://dx.doi.org/10.1097/01.smj.0000251324.81191.cd] [PMID: 17233192]
[129]
Hammoud, G.M.; Almashhrawi, A.; Ibdah, J.A. Usefulness of endoscopic ultrasound-guided fine needle aspiration in the diagnosis of hepatic, gallbladder and biliary tract Lesions. World J. Gastrointest. Oncol., 2014, 6(11), 420-429.
[http://dx.doi.org/10.4251/wjgo.v6.i11.420] [PMID: 25400873]
[130]
Fuccio, L.; Larghi, A. Endoscopic ultrasound-guided fine needle aspiration: How to obtain a core biopsy? Endosc. Ultrasound, 2014, 3(2), 71-81.
[http://dx.doi.org/10.4103/2303-9027.123011] [PMID: 24955336]
[131]
Rana, C.; Krishnani, N.; Kumari, N. Ultrasound-guided fine needle aspiration cytology of gallbladder lesions: a study of 596 cases. Cytopathology, 2016, 27(6), 398-406.
[http://dx.doi.org/10.1111/cyt.12296] [PMID: 26990137]
[132]
Anderson, C.D.; Rice, M.H.; Pinson, C.W.; Chapman, W.C.; Chari, R.S.; Delbeke, D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J. Gastrointest. Surg., 2004, 8(1), 90-97.
[http://dx.doi.org/10.1016/j.gassur.2003.10.003] [PMID: 14746840]
[133]
Kim, J.Y.; Kim, M.H.F.A.; Lee, T.Y.F.A.; Hwang, C.Y.; Kim, J.S.; Yun, S.C.; Lee, S.S.; Seo, D.W.; Lee, S.K. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am. J. Gastroenterol., 2008, 103(5), 1145-1151.
[http://dx.doi.org/10.1111/j.1572-0241.2007.01710.x] [PMID: 18177454]
[134]
Gallamini, A.; Zwarthoed, C.; Borra, A. Positron Emission Tomography (PET) in Oncology. Cancers (Basel), 2014, 6(4), 1821-1889.
[http://dx.doi.org/10.3390/cancers6041821] [PMID: 25268160]
[135]
Jadvar, H.; Henderson, R.W.; Conti, P.S. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J. Comput. Assist. Tomogr., 2007, 31(2), 223-228.
[http://dx.doi.org/10.1097/01.rct.0000237811.88251.d7] [PMID: 17414758]
[136]
Petrowsky, H.; Wildbrett, P.; Husarik, D.B.; Hany, T.F.; Tam, S.; Jochum, W.; Clavien, P.A. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J. Hepatol., 2006, 45(1), 43-50.
[http://dx.doi.org/10.1016/j.jhep.2006.03.009] [PMID: 16690156]
[137]
Garcea, G.; Ong, S.L.; Maddern, G.J. The current role of PET-CT in the characterization of hepatobiliary malignancies. HPB (Oxford), 2009, 11(1), 4-17.
[http://dx.doi.org/10.1111/j.1477-2574.2008.00009.x] [PMID: 19590618]
[138]
The Royal College of Physicians and The Royal College of Radiologist. Evidence-based indications for the use of PETCT in the UK 2013. London: RCP, RCP, 2013, 2013. Ref Type: Abstract
[139]
Sacks, A.; Peller, P.J.; Surasi, D.S.; Chatburn, L.; Mercier, G.; Subramaniam, R.M. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am. J. Roentgenol., 2011, 197(2), W260-5.
[http://dx.doi.org/10.2214/AJR.11.6995] [PMID: 21785051]
[140]
Lamarca, A.; Barriuso, J.; Chander, A.; McNamara, M.G.; Hubner, R.A.; ÓReilly, D.; Manoharan, P.; Valle, J.W. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J. Hepatol., 2019, 71(1), 115-129.
[http://dx.doi.org/10.1016/j.jhep.2019.01.038] [PMID: 30797051]
[141]
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69(3), 89-95.
[http://dx.doi.org/10.1067/mcp.2001.113989] [PMID: 11240971]
[142]
Natsios, A.; Vezakis, A.; Kaparos, G.; Fragulidis, G.; Karakostas, N.; Kouskouni, E.; Logothetis, E.; Polydorou, A. Significance of serum and bile tumor markers in the diagnostic approach of patients with malignant pancreatobiliary disease. J. BUON, 2015, 20(4), 1030-1036.
[PMID: 26416052]
[143]
Lee, D.W. Im, S.A.; Kim, Y.J.; Yang, Y.; Rhee, J.; Na, I.I.; Lee, K.H.; Kim, T.Y.; Han, S.W.; Choi, I.S.; Oh, D.Y.; Kim, J.H.; Kim, T.Y.; Bang, Y.J. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. Cancer Res. Treat., 2017, 49(3), 807-815.
[http://dx.doi.org/10.4143/crt.2016.326] [PMID: 28111425]
[144]
Lin, M.S.; Huang, J.X.; Yu, H. Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. Int. J. Clin. Exp. Med., 2014, 7(3), 744-750.
[PMID: 24753772]
[145]
Scarà, S.; Bottoni, P.; Scatena, R. CA 19-9: Biochemical and Clinical Aspects. Adv. Exp. Med. Biol., 2015, 867, 247-260.
[http://dx.doi.org/10.1007/978-94-017-7215-0_15] [PMID: 26530370]
[146]
Bertram, S.; Padden, J.; Kälsch, J.; Ahrens, M.; Pott, L.; Canbay, A.; Weber, F.; Fingas, C.; Hoffmann, A.C.; Vietor, A.; Schlaak, J.F.; Eisenacher, M.; Reis, H.; Sitek, B.; Baba, H.A. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. J. Clin. Pathol., 2016, 69(7), 619-626.
[http://dx.doi.org/10.1136/jclinpath-2015-203418] [PMID: 26729014]
[147]
Bhatia, V.; Varadarajulu, S. Endoscopic ultrasonography-guided tissue acquisition: How to achieve excellence. Dig. Endosc., 2017, 29(4), 417-430.
[http://dx.doi.org/10.1111/den.12823] [PMID: 28140485]
[148]
Ruys, A.T.; Groot Koerkamp, B.; Wiggers, J.K.; Klümpen, H.J.; ten Kate, F.J.; van Gulik, T.M. Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann. Surg. Oncol., 2014, 21(2), 487-500.
[http://dx.doi.org/10.1245/s10434-013-3286-x] [PMID: 24081803]
[149]
Moeini, A.; Sia, D.; Bardeesy, N.; Mazzaferro, V.; Llovet, J.M. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. Clin. Cancer Res., 2016, 22(2), 291-300.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-3296] [PMID: 26405193]
[150]
Argiles, G.; Dienstmann, R.; Elez, E.; Tabernero, J. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol., 2012, 8(4), 373-389.
[http://dx.doi.org/10.2217/fon.12.20] [PMID: 22515440]
[151]
Amado, R.G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D.J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; Patterson, S.D.; Chang, D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol., 2008, 26(10), 1626-1634.
[http://dx.doi.org/10.1200/JCO.2007.14.7116] [PMID: 18316791]
[152]
Douillard, J.Y.; Oliner, K.S.; Siena, S.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocákova, I.; Ruff, P.; Błasińska-Morawiec, M.; Šmakal, M.; Canon, J.L.; Rother, M.; Williams, R.; Rong, A.; Wiezorek, J.; Sidhu, R.; Patterson, S.D. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med., 2013, 369(11), 1023-1034.
[http://dx.doi.org/10.1056/NEJMoa1305275] [PMID: 24024839]
[153]
Zill, O.A.; Greene, C.; Sebisanovic, D.; Siew, L.M.; Leng, J.; Vu, M.; Hendifar, A.E.; Wang, Z.; Atreya, C.E.; Kelley, R.K.; Van Loon, K.; Ko, A.H.; Tempero, M.A.; Bivona, T.G.; Munster, P.N.; Talasaz, A.; Collisson, E.A. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov., 2015, 5(10), 1040-1048.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0274] [PMID: 26109333]
[154]
Letelier, P.; Riquelme, I.; Hernández, A.H.; Guzmán, N.; Farías, J.G.; Roa, J.C. Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int. J. Mol. Sci., 2016, 17(5), E791.
[http://dx.doi.org/10.3390/ijms17050791] [PMID: 27223281]
[155]
Bonney, G.K.; Craven, R.A.; Prasad, R.; Melcher, A.F.; Selby, P.J.; Banks, R.E. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol., 2008, 9(2), 149-158.
[http://dx.doi.org/10.1016/S1470-2045(08)70027-5] [PMID: 18237849]
[156]
Goyal, L.; Saha, S.K.; Liu, L.Y.; Siravegna, G.; Leshchiner, I.; Ahronian, L.G.; Lennerz, J.K.; Vu, P.; Deshpande, V.; Kambadakone, A.; Mussolin, B.; Reyes, S.; Henderson, L.; Sun, J.E.; Van Seventer, E.E.; Gurski, J.M., Jr; Baltschukat, S.; Schacher-Engstler, B.; Barys, L.; Stamm, C.; Furet, P.; Ryan, D.P.; Stone, J.R.; Iafrate, A.J.; Getz, G.; Porta, D.G.; Tiedt, R.; Bardelli, A.; Juric, D.; Corcoran, R.B.; Bardeesy, N.; Zhu, A.X. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov., 2017, 7(3), 252-263.
[http://dx.doi.org/10.1158/2159-8290.CD-16-1000] [PMID: 28034880]
[157]
ATCC. ATCC, [March 2017]; http://www atcc org2020
[158]
Li, M.; Chen, W.; Zhang, H.; Zhang, Y.; Ke, F.; Wu, X.; Zhang, Y.; Weng, M.; Liu, Y.; Gong, W. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Oncotarget, 2016, 7(50), 83060-83070.
[http://dx.doi.org/10.18632/oncotarget.13067] [PMID: 27825112]
[159]
Sorio, C.; Moore, P.S.; Ennas, M.G.; Tecchio, C.; Bonora, A.; Sartoris, S.; Balzarini, P.; Grigolato, P.; Scarpa, A. A novel cell line and xenograft model of ampulla of Vater adenocarcinoma. Virchows Arch., 2004, 444(3), 269-277.
[http://dx.doi.org/10.1007/s00428-003-0936-6] [PMID: 14677066]
[160]
Nam, A.R.; Kim, J.W.; Cha, Y.; Ha, H.; Park, J.E.; Bang, J.H.; Jin, M.H.; Lee, K.H.; Kim, T.Y.; Han, S.W. Im, S.A.; Kim, T.Y.; Oh, D.Y.; Bang, Y.J. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget, 2016, 7(36), 58007-58021.
[http://dx.doi.org/10.18632/oncotarget.11157] [PMID: 27517322]
[161]
Li, M.; Chen, L.; Qu, Y.; Sui, F.; Yang, Q.; Ji, M.; Shi, B.; Chen, M.; Hou, P. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing. Oncotarget, 2017, 8(22), 36319-36330.
[http://dx.doi.org/10.18632/oncotarget.16751] [PMID: 28422736]
[162]
Wang, Y.; Ding, X.; Wang, S.; Moser, C.D.; Shaleh, H.M.; Mohamed, E.A.; Chaiteerakij, R.; Allotey, L.K.; Chen, G.; Miyabe, K.; McNulty, M.S.; Ndzengue, A.; Barr Fritcher, E.G.; Knudson, R.A.; Greipp, P.T.; Clark, K.J.; Torbenson, M.S.; Kipp, B.R.; Zhou, J.; Barrett, M.T.; Gustafson, M.P.; Alberts, S.R.; Borad, M.J.; Roberts, L.R. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett., 2016, 380(1), 163-173.
[http://dx.doi.org/10.1016/j.canlet.2016.05.017] [PMID: 27216979]
[163]
Peng, H.; Zhang, Q.; Li, J.; Zhang, N.; Hua, Y.; Xu, L.; Deng, Y.; Lai, J.; Peng, Z.; Peng, B.; Chen, M.; Peng, S.; Kuang, M. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget, 2016, 7(13), 17220-17229.
[http://dx.doi.org/10.18632/oncotarget.7948] [PMID: 26967384]
[164]
Liang, H.B.; Cao, Y.; Ma, Q.; Shu, Y.J.; Wang, Z.; Zhang, F.; Ye, Y.Y.; Li, H.F.; Xiang, S.S.; Song, X.L.; Xu, Y.; Zhang, Y.C.; Bao, R.F.; Yuan, R.Y.; Zhang, Y.J.; Hu, Y.P.; Jiang, L.; Li, M.L.; Wang, X.A.; Wu, X.S.; Wu, W.G.; Zhao, S.; Fand, Y.; Cui, X.P.; Lu, Y.S.; Zhou, J.; Zheng, L.; Gong, W.; Liu, Y.B. MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer. Cell. Physiol. Biochem., 2017, 41(5), 2117-2131.
[http://dx.doi.org/10.1159/000475454] [PMID: 28427077]
[165]
Zhao, S.; Cao, Y.; Liu, S.B.; Wang, X.A.; Bao, R.F.; Shu, Y.J.; Hu, Y.P.; Zhang, Y.J.; Jiang, L.; Zhang, F.; Liang, H.B.; Li, H.F.; Ma, Q.; Xu, Y.; Wang, Z.; Zhang, Y.C.; Chen, L.; Zhou, J.; Liu, Y.B. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. J. Exp. Clin. Cancer Res., 2016, 35(1), 97-0370.
[http://dx.doi.org/10.1186/s13046-016-0370-7] [PMID: 27317099]
[166]
Zender, S.; Nickeleit, I.; Wuestefeld, T.; Sörensen, I.; Dauch, D.; Bozko, P.; El-Khatib, M.; Geffers, R.; Bektas, H.; Manns, M.P.; Gossler, A.; Wilkens, L.; Plentz, R.; Zender, L.; Malek, N.P. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell, 2013, 23(6), 784-795.
[http://dx.doi.org/10.1016/j.ccr.2013.04.019] [PMID: 23727022]
[167]
Saha, S.K.; Parachoniak, C.A.; Ghanta, K.S.; Fitamant, J.; Ross, K.N.; Najem, M.S.; Gurumurthy, S.; Akbay, E.A.; Sia, D.; Cornella, H.; Miltiadous, O.; Walesky, C.; Deshpande, V.; Zhu, A.X.; Hezel, A.F.; Yen, K.E.; Straley, K.S.; Travins, J.; Popovici-Muller, J.; Gliser, C.; Ferrone, C.R.; Apte, U.; Llovet, J.M.; Wong, K.K.; Ramaswamy, S.; Bardeesy, N. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature, 2014, 513(7516), 110-114.
[http://dx.doi.org/10.1038/nature13441] [PMID: 25043045]
[168]
Kalamarides, M.; Niwa-Kawakita, M.; Leblois, H.; Abramowski, V.; Perricaudet, M.; Janin, A.; Thomas, G.; Gutmann, D.H.; Giovannini, M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev., 2002, 16(9), 1060-1065.
[http://dx.doi.org/10.1101/gad.226302] [PMID: 12000789]
[169]
Xu, X.; Kobayashi, S.; Qiao, W.; Li, C.; Xiao, C.; Radaeva, S.; Stiles, B.; Wang, R.H.; Ohara, N.; Yoshino, T.; LeRoith, D.; Torbenson, M.S.; Gores, G.J.; Wu, H.; Gao, B.; Deng, C.X. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J. Clin. Invest., 2006, 116(7), 1843-1852.
[http://dx.doi.org/10.1172/JCI27282] [PMID: 16767220]
[170]
Ko, K.S.; Peng, J.; Yang, H. Animal models of cholangiocarcinoma. Curr. Opin. Gastroenterol., 2013, 29(3), 312-318.
[http://dx.doi.org/10.1097/MOG.0b013e32835d6a3e] [PMID: 23434850]
[171]
Liu, W.; Chen, J.R.; Hsu, C.H.; Li, Y.H.; Chen, Y.M.; Lin, C.Y.; Huang, S.J.; Chang, Z.K.; Chen, Y.C.; Lin, C.H.; Gong, H.Y.; Lin, C.C.; Kawakami, K.; Wu, J.L. A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. Hepatology, 2012, 56(6), 2268-2276.
[http://dx.doi.org/10.1002/hep.25914] [PMID: 22729936]
[172]
Kiguchi, K.; Carbajal, S.; Chan, K.; Beltrán, L.; Ruffino, L.; Shen, J.; Matsumoto, T.; Yoshimi, N.; DiGiovanni, J. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res., 2001, 61(19), 6971-6976.
[PMID: 11585718]
[173]
Boj, S.F.; Hwang, C.I.; Baker, L.A.; Chio, I.I.; Engle, D.D.; Corbo, V.; Jager, M.; Ponz-Sarvise, M.; Tiriac, H.; Spector, M.S.; Gracanin, A.; Oni, T.; Yu, K.H.; van Boxtel, R.; Huch, M.; Rivera, K.D.; Wilson, J.P.; Feigin, M.E.; Öhlund, D.; Handly-Santana, A.; Ardito-Abraham, C.M.; Ludwig, M.; Elyada, E.; Alagesan, B.; Biffi, G.; Yordanov, G.N.; Delcuze, B.; Creighton, B.; Wright, K.; Park, Y.; Morsink, F.H.; Molenaar, I.Q.; Borel Rinkes, I.H.; Cuppen, E.; Hao, Y.; Jin, Y.; Nijman, I.J.; Iacobuzio-Donahue, C.; Leach, S.D.; Pappin, D.J.; Hammell, M.; Klimstra, D.S.; Basturk, O.; Hruban, R.H.; Offerhaus, G.J.; Vries, R.G.; Clevers, H.; Tuveson, D.A. Organoid models of human and mouse ductal pancreatic cancer. Cell, 2015, 160(1-2), 324-338.
[http://dx.doi.org/10.1016/j.cell.2014.12.021] [PMID: 25557080]
[174]
Bridgewater, J.; Lopes, A.; Palmer, D.; Cunningham, D.; Anthoney, A.; Maraveyas, A.; Madhusudan, S.; Iveson, T.; Valle, J.; Wasan, H. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br. J. Cancer, 2016, 114(9), 965-971.
[http://dx.doi.org/10.1038/bjc.2016.64] [PMID: 27115567]
[175]
Bottomley, A.; Vachalec, S.; Bjordal, K.; Blazeby, J.; Flechtner, H.; Ruyskart, P. The development and utilisation of the European Organisation for research and treatment of cancer quality of life group item bank. Eur. J. Cancer, 2002, 38(12), 1611-1614.
[http://dx.doi.org/10.1016/S0959-8049(02)00125-9] [PMID: 12142050]
[176]
Aaronson, N.K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N.J.; Filiberti, A.; Flechtner, H.; Fleishman, S.B.; de Haes, J.C. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst., 1993, 85(5), 365-376.
[http://dx.doi.org/10.1093/jnci/85.5.365] [PMID: 8433390]
[177]
Cella, D.; Butt, Z.; Kindler, H.L.; Fuchs, C.S.; Bray, S.; Barlev, A.; Oglesby, A. Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Qual. Life Res., 2013, 22(5), 1105-1112.
[http://dx.doi.org/10.1007/s11136-012-0217-4] [PMID: 22678353]
[178]
Fitzsimmons, D.; Johnson, C.D.; George, S.; Payne, S.; Sandberg, A.A.; Bassi, C.; Beger, H.G.; Birk, D.; Büchler, M.W.; Dervenis, C.; Fernandez Cruz, L.; Friess, H.; Grahm, A.L.; Jeekel, J.; Laugier, R.; Meyer, D.; Singer, M.W.; Tihanyi, T. EORTC Study Group on Quality of Life. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur. J. Cancer, 1999, 35(6), 939-941.
[http://dx.doi.org/10.1016/S0959-8049(99)00047-7] [PMID: 10533475]
[179]
Butt, Z.; Parikh, N.D.; Beaumont, J.L.; Rosenbloom, S.K.; Syrjala, K.L.; Abernethy, A.P.; Benson, A.B., III; Cella, D. Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI). Cancer, 2012, 118(23), 5997-6004.
[http://dx.doi.org/10.1002/cncr.27588] [PMID: 22605658]
[180]
Friend, E.; Yadegarfar, G.; Byrne, C.; Johnson, C.D.; Sezer, O.; Pucciarelli, S.; Pereira, S.P.; Chie, W.C.; Banfield, A.; Ramage, J.K. EORTC Quality of Life Group. Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br. J. Cancer, 2011, 104(4), 587-592.
[http://dx.doi.org/10.1038/sj.bjc.6606086] [PMID: 21266979]
[181]
Kaupp-Roberts, S.D.; Yadegarfar, G.; Friend, E.; O’Donnell, C.M.; Valle, J.W.; Byrne, C.; Bahar, I.; Finch-Jones, M.; Gillmore, R.; Johnson, C.D.; Pereira, S.P.; Wiggers, J.K.; Pinto, M.; Al-Sarireh, B.; Ramage, J.K. Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. Br. J. Cancer, 2016, 115(9), 1032-1038.
[http://dx.doi.org/10.1038/bjc.2016.284] [PMID: 27673364]

Rights & Permissions Print Cite
Article Metrics
36
© 2025 Bentham Science Publishers | Privacy Policy